Connect with us


Analysts: These 3 Penny Stocks May Very Well Be Worth the Risk

Analysts: These 3 Penny Stocks May Very Well Be Worth the Risk



When searching for risk/reward plays, look no further than penny stocks. These names trading for under $5 per share are considered to be some of the most controversial on the Street, and divide market watchers into two factions: critics and fans.

The former brings a valid argument to the table. Stocks don’t just end up trading at such low levels; typically, there’s a very real reason for their bargain price tags. This can be weak fundamentals or headwinds that are too strong to overcome.

As for the latter, the potential for an investment worth only pocket change to appreciate even a seemingly insignificant amount, the result of which could be massive percentage gains, is too enticing to ignore. Not to mention the low share price means you can carve out a bigger stake for less money upfront.

The implication for investors? Due diligence is essential, as some penny stocks might not have what it takes to climb their way back up.

Taking all of this into consideration, we used TipRanks’ database to pinpoint three penny stocks in the healthcare sector with promising long-term growth prospects. Each gets a thumbs up from the analyst community, scoring a “Strong Buy” consensus rating, and boasts huge upside potential. We are talking returns of at least 100% over the next months.

Accuray Inc. (ARAY)

With its cutting-edge CyberKnife S7 System, Accuray provides both practices and clinicians with the capabilities to deliver personalized stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT) and hypofractionated radiotherapy treatments. Given its $2.28 share price, some believe that now is the ideal time to get on board.

Cowen analyst Joshua Jennings acknowledges that COVID-19 has brought about strong headwinds for the radiation oncology space as a whole, with multiple hospitals re-prioritizing their capital equipment purchasing plans. Yet, the analyst’s bullish thesis on ARAY remains very much intact, with Jennings arguing that the rebound should be the focus here. He calls for sequential improvements throughout fiscal 2021.

Expounding on this, Jennings stated, “We believe the company is well-positioned to weather the storm and capitalize on its longer-term opportunities. ARAY has multiple attractive growth drivers that will kick back in during normalized periods. Its strategic standing in China, combined with its replacement cycle prospects and overall radiation oncology market dynamics, fuels our optimistic outlook for a sequential recovery trajectory in fiscal 2021 and the return to growth in fiscal 2022 (off of a pre-COVID-19 revenue run rate).”

"We would highlight that ARAY shares remain deeply discounted at under 0.7x forward sales and represent an attractive value proposition considering the company was on track to deliver an 8-12% revenue CAGR prior to the COVID-19 crisis," the analyst added.

To this end, Jennings rates ARAY an Outperform (i.e. Buy) along with an $8.00 price target. Should this target be met, a twelve-month gain of 250% could be in store. (To watch Jennings’ track record, click here)   

Like Jennings, other analysts also take a bullish approach. ARAY's Strong Buy consensus rating breaks down into 3 Buy ratings received in the last three months. Additionally, the $8 average price target matches Jennings’. (See ARAY stock analysis on TipRanks)

Ziopharm Oncology (ZIOP)

Utilizing the body’s immune response, Ziopharm Oncology develops immuno-oncology gene and cell therapies to fight blood cancers and solid tumors. Based on its latest data readout and $3.27 share price, it’s no wonder this name is on Wall Street’s radar.

Recently, ZIOP released data on its controlled IL-12 program in monotherapy and combination in glioblastoma (GBM). Writing for Cantor, 5-star analyst Alethia Young believes both the monotherapy and combination results support the promising efficacy trends that were already seen. Also encouraging, she highlights the fact that the “monotherapy study survival data (now fairly mature) clearly support further development.”

Looking more closely at the survival data, in a subgroup of 20 patients that were given low-dose steroids and unifocal disease, 16.2 months of median survival were witnessed, with the mean follow up landing at 14.1 months. As Young was expecting to see mean survival come in at 6-12 months, she is optimistic about the program’s potential.

As for the combination portion, even though “median follow was shorter than monotherapy at 8.3 months,” Young pointed out, “IL-12 helps put T cells into the tumor, which could create PD-1 on the surface receptor, suggesting that adding PD-1 could be synergistic by turning cold tumors (little immune activity) into hot ones.”

To sum it all up, Young commented, “Refractory GBM remains an area of high unmet need. Importantly, we also think either monotherapy or combination provide shots on goal to improve the standard of care. So far, the safety has looked good in the main study as well.”

It should be noted that the IL-12 and GBM space has faced challenges in the past, which has contributed to the skepticism surrounding ZIOP’s pipeline. However, everything that the company has going for it prompted Young to stay with the bulls. Along with an Overweight rating, she left her price target at $6. This figure implies shares could climb 83% higher in the next year. (To watch Young’s track record, click here)   

All in all, other analysts are on the same page. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the $6.50 average price target, which is more aggressive than Young’s, the upside potential comes in at 99%. (See Ziopharm stock analysis on TipRanks)

Entasis Therapeutics (ETTX)

Last but not least we have Entasis Therapeutics, which develops molecules that could potentially address and overcome mechanisms of antibiotic resistance in specific bacterial pathogens. Currently going for $2.98 apiece, several members of the Street believe that its share price reflects an attractive entry point.

ETTX is slated to release topline data for its Phase 3 ATTACK study, which is evaluating SUL-DUR (ETX2514SUL), a fixed-dose combination of the broad-spectrum beta-lactamase inhibitor ETX2514 with sulbactam, as a treatment for patients with pneumonia or bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. COVID-19 has had an impact on the study’s enrollment, but Wedbush analyst Robert Driscoll remains squarely in the bull camp, pointing out that efforts have been made to limit the impact on the trial timeline.

Driscoll added, “We expect enrollment will be more rapid once sites China open recruitment – ETTX’s partner Zai Labs is co-enrolling up to 20% of the patients in ATTACK, which will likely allow for approval in China should ATTACK be successful. We believe the study has a high chance of success given demonstrated in vitro activity against a panel of Acinetobacter strains, dose proportional PK in healthy volunteers within the predicted therapeutic range, and a BAL study showing equivalent lung penetration for SUL-DUR to avibactam (approved for HABP/ VAP in combination with ceftazidime).”

Along with this, Phase 2 data demonstrated SUL-DUR was generally well tolerated in cUTI patients. It also didn’t produce serious adverse events, with the adverse event profile resembling the placebo/IMI arm.

It should be noted that the ongoing Phase 3 uncomplicated gonorrhea study has been temporarily suspended. However, Driscoll tells clients that topline data is still set for publication in 2H:21. Speaking to the potential opportunity, he said, “Phase 2 data, published in NEJM, demonstrated 100% success rate for 47 urogenital gonorrhea patients treated with 3 g zoliflodacin vs. 100% patients treated with an intramuscular injection of ceftriaxone. We see a significant opportunity for ETTX given the lack of recommended oral antibiotics as an alternative to intramuscular administered ceftriaxone, which is currently the only recommended option.”

As the recent private placement could raise $31.7 million and extend its cash runway into the middle of 2021, Driscoll likes what he’s seeing. To this end, he maintained an Outperform (i.e. Buy) rating along with a $7 price target, which leaves room for shares to skyrocket 135% in the next twelve months. (To watch Driscoll’s track record, click here)      

Do other analysts agree with Driscoll? They do. Only Buy ratings, 4, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. At $6.25, the average price target puts the potential twelve-month gain at 110%. (See ETTX stock-price forecast on TipRanks)

To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

The post Analysts: These 3 Penny Stocks May Very Well Be Worth the Risk appeared first on TipRanks Financial Blog.

Read More

Continue Reading


What Follows US Hegemony

What Follows US Hegemony

Authored by Vijay Prashad via,

On 24 February 2023, the Chinese Foreign Ministry released a…



What Follows US Hegemony

Authored by Vijay Prashad via,

On 24 February 2023, the Chinese Foreign Ministry released a twelve-point plan entitled ‘China’s Position on the Political Settlement of the Ukraine Crisis’.

This ‘peace plan’, as it has been called, is anchored in the concept of sovereignty, building upon the well-established principles of the United Nations Charter (1945) and the Ten Principles from the Bandung Conference of African and Asian states held in 1955. The plan was released two days after China’s senior diplomat Wang Yi visited Moscow, where he met with Russia’s President Vladimir Putin.

Russia’s interest in the plan was confirmed by Kremlin spokesperson Dmitry Peskov shortly after the visit: ‘Any attempt to produce a plan that would put the [Ukraine] conflict on a peace track deserves attention. We are considering the plan of our Chinese friends with great attention’.

Ukraine’s President Volodymyr Zelensky welcomed the plan hours after it was made public, saying that he would like to meet China’s President Xi Jinping as soon as possible to discuss a potential peace process. France’s President Emmanuel Macron echoed this sentiment, saying that he would visit Beijing in early April. There are many interesting aspects of this plan, notably a call to end all hostilities near nuclear power plants and a pledge by China to help fund the reconstruction of Ukraine. But perhaps the most interesting feature is that a peace plan did not come from any country in the West, but from Beijing.

When I read ‘China’s Position on the Political Settlement of the Ukraine Crisis’, I was reminded of ‘On the Pulse of Morning’, a poem published by Maya Angelou in 1993, the rubble of the Soviet Union before us, the terrible bombardment of Iraq by the United States still producing aftershocks, the tremors felt in Afghanistan and Bosnia. The title of this newsletter, ‘Birth Again the Dream of Global Peace and Mutual Respect’, sits at the heart of the poem. Angelou wrote alongside the rocks and the trees, those who outlive humans and watch us destroy the world. Two sections of the poem bear repeating:

Each of you, a bordered country,
Delicate and strangely made proud,
Yet thrusting perpetually under siege.
Your armed struggles for profit
Have left collars of waste upon
My shore, currents of debris upon my breast.
Yet today I call you to my riverside,
If you will study war no more. Come,
Clad in peace, and I will sing the songs
The Creator gave to me when I and the
Tree and the rock were one.
Before cynicism was a bloody sear across your
Brow and when you yet knew you still
Knew nothing.
The River sang and sings on.

History, despite its wrenching pain
Cannot be unlived, but if faced
With courage, need not be lived again.

History cannot be forgotten, but it need not be repeated. That is the message of Angelou’s poem and the message of the study we released last week, Eight Contradictions of the Imperialist ‘Rules-Based Order’.

In October 2022, Cuba’s Centre for International Policy Research (CIPI) held its 7th Conference on Strategic Studies, which studied the shifts taking place in international relations, with an emphasis on the declining power of the Western states and the emergence of a new confidence in the developing world. There is no doubt that the United States and its allies continue to exercise immense power over the world through military force and control over financial systems. But with the economic rise of several developing countries, with China at their head, a qualitative change can be felt on the world stage. An example of this trend is the ongoing dispute amongst the G20 countries, many of which have refused to line up against Moscow despite pressure by the United States and its European allies to firmly condemn Russia for the war in Ukraine. This change in the geopolitical atmosphere requires precise analysis based on the facts.

To that end, our latest dossier, Sovereignty, Dignity, and Regionalism in the New International Order (March 2023), produced in collaboration with CIPI, brings together some of the thinking about the emergence of a new global dispensation that will follow the period of US hegemony.

The text opens with a foreword by CIPI’s director, José R. Cabañas Rodríguez, who makes the point that the world is already at war, namely a war imposed on much of the world (including Cuba) by the United States and its allies through blockades and economic policies such as sanctions that strangle the possibilities for development. As Greece’s former Finance Minister Yanis Varoufakis said, coups these days ‘do not need tanks. They achieve the same result with banks’.

The US is attempting to maintain its position of ‘single master’ through an aggressive military and diplomatic push both in Ukraine and Taiwan, unconcerned about the great destabilisation this has inflicted upon the world. This approach was reflected in US Defence Secretary Lloyd Austin’s admission that ‘We want to see Russia weakened’ and in US House Foreign Affairs Committee Chairman Michael McCaul’s statement that ‘Ukraine today – it’s going to be Taiwan tomorrow’. It is a concern about this destabilisation and the declining fortunes of the West that has led most of the countries in the world to refuse to join efforts to isolate Russia.

As some of the larger developing countries, such as China, Brazil, India, Mexico, Indonesia, and South Africa, pivot away from reliance upon the United States and its Western allies, they have begun to discuss a new architecture for a new world order. What is quite clear is that most of these countries – despite great differences in the political traditions of their respective governments – now recognise that the United States ‘rules-based international order’ is no longer able to exercise the authority it once had. The actual movement of history shows that the world order is moving from one anchored by US hegemony to one that is far more regional in character. US policymakers, as part of their fearmongering, suggest that China wants to take over the world, along the grain of the ‘Thucydides Trap’ argument that when a new aspirant to hegemony appears on the scene, it tends to result in war between the emerging power and existing great power. However, this argument is not based on facts.

Rather than seek to generate additional poles of power – in the mould of the United States – and build a ‘multipolar’ world, developing countries are calling for a world order rooted in the UN Charter as well as strong regional trade and development systems. ‘This new internationalism can only be created – and a period of global Balkanisation avoided’, we write in our latest dossier, ‘by building upon a foundation of mutual respect and strength of regional trade systems, security organisations, and political formations’. Indicators of this new attitude are present in the discussions taking place in the Global South about the war in Ukraine and are reflected in the Chinese plan for peace.

Our dossier analyses at some length this moment of fragility for US power and its ‘rules-based international order’. We trace the revival of multilateralism and regionalism, which are key concepts of the emerging world order. The growth of regionalism is reflected in the creation of a host of vital regional bodies, from the Community of Latin American and Caribbean States (CELAC) to the Shanghai Cooperation Organisation (SCO), alongside increasing regional trade (with the BRICS bloc being a kind of ‘regionalism plus’ for our period). Meanwhile, the emphasis on returning to international institutions for global decision-making, as evidenced by the formation of the Group of Friends in Defence of the UN Charter, for example, illustrates the reinvigorated desire for multilateralism.

The United States remains a powerful country, but it has not come to terms with the immense changes taking place in the world order. It must temper its belief in its ‘manifest destiny’ and recognise that it is nothing more than another country amongst the 193 members states of the United Nations. The great powers – including the United States – will either find ways to accommodate and cooperate for the common good, or they will all collapse together.

At the start of the pandemic, the head of the World Health Organisation, Dr Tedros Adhanom Ghebreyesus, urged the countries of the world to be more collaborative and less confrontational, saying that ‘this is the time for solidarity, not stigma’ and repeating, in the years since, that nations must ‘work together across ideological divides to find common solutions to common problems’.

These wise words must be heeded.

Tyler Durden Sun, 03/19/2023 - 23:30

Read More

Continue Reading


Royal Caribbean Officially Makes Controversial Change

The cruise line has made a controversial change that some passengers will love while others will be angry.



The cruise line has made a controversial change that some passengers will love while others will be angry.

During the early days of the cruise industry's comeback from the covid pandemic, Royal Caribbean outlawed smoking in the casino. At the time, the Centers for Disease Control (CDC) required passengers to wear masks in public areas of the ship except when eating or drinking while stationary.

Smoking was, at first, a sort of loophole. People would smoke in the casino and remove their masks (or at least move them to the side) while playing slot machines. That basically meant that unlike drinking, where your mask could be moved and then replaced for a sip, smokers were essentially not wearing a mask.

DON'T MISS: Carnival Cruise Line Comments on a Possible (Very) Adult Change

Royal Caribbean (RCL) - Get Free Report closed that loop by fully outlawing smoking in its casinos while masks were still required. That was something that smokers weren't happy about, but probably understood given how large a role the CDC was playing in setting cruise ship rules.

Once the CDC stopped requiring masks (and regulating cruise ships at all), Royal Caribbean reverted to its pre-pandemic smoking policies. That meant that every casino on its ships had a smoking section. Technically, smoking is only allowed when actually playing a slot machine, but that's hard to enforce and the casinos quickly filled back up with smoke.

Now, the cruise line has officially made a long-rumored move that should make non-smokers really happy while angering a whole different group of the cruise line's passengers.

Image source: Matt Cardy/Getty Images

Oasis-Class Ships Getting Non-Smoking Area

Wonder of the Seas, the newest member of Royal Caribbean's Oasis class was originally built to sail out of China. It was moved to Florida due to the covid pandemic which created a sort of happy accident for non-smokers.

The ship was built with a secondary casino that was originally intended as a high rollers room. Once the ship was repurposed to sail from the United States, that smaller casino was shifted from an area designed to cater to big-money players into a non-smoking casino.

For months, it has been rumored that the cruise line would turn the "Jazz on 4" space -- the same location as the non-smoking "Golden Roon" on Wonder of the Seas -- into similar non-smoking casinos. Royal Caribbean never commented on those rumors, but it did warn passengers on some sailings that service in the Diamond Lounge, an area next to Jazz on 4 reserved for Diamond and higher members of the company's loyalty program, would be disrupted due to construction.

The results of that construction have been revealed on another Oasis-class ship, Harmony of the Seas. Johnny Travalor shared pictures of the new casino in a Facebook group for fans of Royal Caribbean's casinos.

"The brand new non-smoking casino on Harmony officially opened today and I have been here since the opening playing, donating!" he shared.

That's not official confirmation that all Oasis-class ships will have Jazz on 4 turned into a non-smoking casino, but all signs point in that direction.

Royal Caribbean Makes Some Passengers Mad

No change on a cruise ship will make all passengers happy. Some Royal Caribbean gamblers have suggested that the non-smoking area, which is much smaller than the original casino, should be the smoking area.

"Maybe once they see the non-smokers are bursting at the seam in that space and the smoking casino isn’t as crowded they will reverse it," Barb Boyer Green shared.

"That should be the smoking room...seems like the non-smokers are being put in a closet," Maureen Ethier added.

Not all passengers, however, are upset because of the size of the non-smoking area. Some are lamenting the loss of Jazz on 4, which hosted live jazz music.

"I think this is an overall loss, with now an entertainment area being taken over on this ship. I always enjoyed the jazz club and this will do nothing for the smell of the ship, net loss for all passengers" Justin Rogers wrote.

"It was our fav such a sad day. It was our escape, great talent, romantic, not another venue like it. Such a shame," added Julia Doumad.

Read More

Continue Reading


The limits of expert judgment: Lessons from social science forecasting during the pandemic

A sobering picture emerges from a study testing social scientists’ ability to predict societal change during the COVID-19 pandemic.



To find out how well social scientists can predict societal change, researchers ran the largest forecasting initiative in the field’s history. Here’s what they found. (Shutterstock)

Imagine being a policymaker at the beginning of the COVID-19 pandemic. You have to decide which actions to recommend, how much risk to tolerate and what sacrifices to ask your citizens to bear.

Who would you turn to for an accurate prediction about how people would react? Many would recommend going to the experts — social scientists. But we are here to tell you this would be bad advice.

As psychological scientists with decades of combined experience studying decision-making, wisdom, expert judgment and societal change, we hoped social scientists’ predictions would be accurate and useful. But we also had our doubts.

Our discipline has been undergoing a crisis due to failed study replications and questionable research practices. If basic findings can’t be reproduced in controlled experiments, how confident can we be that our theories can explain complex real-world outcomes?

Predicting social change

To find out how well social scientists could predict societal change, we ran the largest forecasting initiative in our field’s history using predictions about change in the first year of the COVID-19 pandemic as a test case.

To do this, we tested how well social scientists could predict societal change in two ways. First, we asked social scientists for quick guesses about how things would change over the next two years of the pandemic.

Second, we ran a competition where over 100 teams of social scientists with access to historical data made month-by-month forecasts. We formally assessed their predictions for a range of social sciences phenomena, including changes in prejudice, subjective well-being, violence, individualism and political polarization between May 2020 and May 2021.

Forecasting errors when social scientists were predicting social and psychological consequences of COVID-19.
Results of the social science forecasting tournaments by the Forecasting Collaborative conducted during the 2020-2021 years of the COVID-19 pandemic. (Igor Grossmann)

Our findings, detailed in peer-reviewed papers in Nature Human Behaviour and in American Psychologist, paint a sobering picture. Despite the causal nature of most theories in the social sciences, and the fields’ emphasis on prediction in controlled settings, social scientists’ forecasts were generally not very good.

In both papers, we found that experts’ predictions were generally no more accurate than those made by samples of the general public. Further, their predictions were often worse than predictions generated by simple statistical models.

Improving predictions

Our studies did still give us reasons to be optimistic. First, forecasts were more accurate when teams had specific expertise in the domain they were making predictions in. If someone was an expert in depression, for example, they were better at predicting societal trends in depression.

Second, when teams were made up of scientists from different fields working together, they tended to do better at forecasting. Finally, teams that used simpler models to generate their predictions and made use of past data generally outperformed those that didn’t.

These findings suggest that, despite the poor performance of the social scientists in our studies, there are steps scientists can take to improve their accuracy at this type of forecasting.

An infographic of the map of the world with blue dots indicating where participants in the World after COVID were from
Results of the World after COVID project documenting the diversity and uncertainty in predictions of the social and psychological consequences of the pandemic among members of the world’s scientific community. (Igor Grossmann)

Our research also found that, compared to lay people, social scientists were more aware of the herculean nature of the task at hand. In our studies, they expressed uncertainty and less confidence than lay people when making forecasts.

Similarly, social scientists expressed uncertainty in their open-ended predictions for the World after COVID project, a video series we conducted with eminent scholars in the first year of the pandemic.

Thus, social scientists still have some wisdom to offer, reminding us of the uncertainty and the need for humility when forecasting the future.

A call to action

Our work highlights the importance of developing reliable sources of data and suggests strategies that can improve the accuracy of such forecasts.

These results are a call to action for the scientific community to continue developing better methods for predicting societal change so the public can rely on scientists in times of crisis.

Our projects show that expert prediction of societal change during the COVID-19 pandemic was far from perfect. But they also suggest ways such predictions can be improved. By drawing on specific expertise, collaborating across disciplines and making data-driven models, social scientists can produce more accurate and useful forecasts for policymakers and the public.

The scientific community should strive to develop better methods for predicting societal change, while acknowledging the uncertainty and complexity involved. Policymakers should appreciate the value of expert insight, but also be aware of its limitations and potential biases. If we want to predict the future, or shape it for that matter, than a bit of humility would likely help.

Igor Grossmann receives funding from the Social Sciences and Humanities Research Council of Canada, Ontario Ministry of Research, Innovation and Science, The John Templeton Foundation, and the Templeton World Charity Foundation.

Cendri Hutcherson receives funding from the Social Sciences and Humanities Research Council of Canada, the Natural Sciences and Engineering Research Council of Canada, the Canada Foundation for Innovation, the Ontario Ministry of Research and Innovation, and the National Institutes for Mental Health (USA).

Michael Varnum has received funding from the National Science Foundation (USA), the US Fulbright Program, and the China Postdoctoral Science Foundation.

Read More

Continue Reading